Nadroparin calcium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nadroparin calcium
Systematic (IUPAC) name
(4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
Clinical data
Trade names Fraxiparine, Fraxodi
AHFS/Drugs.com International Drug Names
Routes of
administration
SC (except for haemodialysis)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 89% (SC dose)
Biological half-life 3.7 hours (SC dose)
Excretion clearance 21.4mL/min (+/- 7)
Identifiers
CAS Number 9041-08-1 YesY
ATC code B01AB06 (WHO)
DrugBank DB08813 YesY
ChemSpider none
UNII LIA7Z4002P YesY
KEGG D07510 YesY
Chemical data
Molar mass 4300 g/mol
 NYesY (what is this?)  (verify)

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.[1]

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.[1]

References[edit]

External links[edit]